Upgrade to SI Premium - Free Trial

U.S. Physical Therapy Reports Record Quarterly Earnings

November 5, 2020 8:00 AM

HOUSTON--(BUSINESS WIRE)-- U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported record results for the third quarter ended September 30, 2020.

For the third quarter ended September 30, 2020, USPH’s Operating Results (as defined below), was $11.1 million, or $0.86 per diluted share, as compared to $9.0 million, or $0.71 per diluted share in the third quarter of 2019. Included in the recent quarter was $0.2 million net of allocation to non-controlling interests and after-tax of Relief Funds, or $.01 per share. For the third quarter ended September 30, 2020, USPH’s Operating Results, without the Relief Funds, was $10.9 million, or $0.85 per diluted share. Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders per the consolidated statement of net income plus charges incurred for closure costs less gain on sale of partnership interest and clinics, less allocated non-controlling interests, and excludes expenses associated with the CFO recruitment, all net of tax. The earnings per share from Operating Results also excludes the impact of the revaluation of redeemable non-controlling interest. For the third quarter ended September 30, 2020, USPH’s net income attributable to its shareholders, in accordance with GAAP, was $10.9 million as compared to $9.0 million for the comparable period of 2019. Inclusive of the credit or charge for the revaluation of non-controlling interest, net of tax, used to compute diluted earnings per share in accordance with GAAP in the 2020 Third Quarter, the amount is $7.8 million, or $0.61 per share, as compared to $8.4 million, or $0.66 per share in the third quarter last year. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but charged or credited directly to retained earnings; however, the charge or credit for this change is included in the earnings per basic and diluted share calculations.

For the nine months ended September 30, 2020, USPH’s Operating Results, including Relief Funds, was $24.6 million, or $1.92 per diluted share, as compared to $27.8 million, or $2.18 per diluted share in 2019. For the nine months ended September 30, 2020, USPH’s Operating Results, without Relief Funds, was $19.7 million, or $1.54 per diluted share. For the nine months ended September 30, 2020, USPH’s net income attributable to its shareholders, in accordance with GAAP, was $22.2 million as compared to $32.1 million for the comparable period of 2019. Inclusive of the credit or charge for the revaluation of non-controlling interest, net of tax, used to compute diluted earnings per share, in accordance with GAAP, in the 2020 first nine months ended September 30, 2020, the amount is $23.0 million, or $1.80 per share, as compared to $24.2 million, or $1.90 per share. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but charged or credited directly to retained earnings; however, the charge or credit for this change is included in the earnings per basic and diluted share calculation. See the schedule on page 12 for the computation of diluted earnings per share and discussion of Relief Funds below.

As previously disclosed in a series of filings with the SEC and further described in detail in our Quarterly Report on Form 10-Q for the first and second quarters, the Company’s results have been negatively impacted by the effects of the COVID-19 pandemic. Management has taken a number of steps to reduce costs, make up for operating losses incurred in March and April, and increase profits subsequently. The Company continues to experience somewhat lower physical therapy patient volumes; however revenues improved significantly in the 2020 third quarter compared to the 2020 second quarter. The Company’s average physical therapy patient volumes per day per clinic were 26.2, 18.9, and 25.8, respectively, in the first three quarters of 2020. The Company’s industrial injury prevention business has been less affected by the pandemic and is currently running at slightly less than its pre-COVID-19 revenue levels.

Third Quarter 2020 Compared to Third Quarter 2019

First Nine Months 2020 Compared to First Nine Months 2019

Medicare Accelerated and Advance Payment Program (“MAAPP Funds”)

In response to the COVID-19 pandemic, the federal government approved the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act allowed for qualified healthcare providers to receive advanced payments under the existing MAAPP Funds during the COVID-19 pandemic. Under this program, healthcare providers could choose to receive advanced payments for future Medicare services provided. The Company applied for and received approval from Centers for Medicare & Medicaid Services (“CMS”) in April 2020. The Company recorded these payments as a liability until all performance obligations have been met as the payments were made on behalf of patients before services were provided. Currently, MAAPP funds received are required to be applied to future Medicare billings commencing in August 2021, with all such remaining amounts required to be repaid by January 2024. Beginning January 2024, any unpaid balance will begin accruing interest. The Company currently intends to repay funds prior to August 2021. Included in cash and cash equivalents and accrued liabilities at September 30, 2020 is $12.9 million of MAAPP Funds.

Relief Funds

On March 27, 2020, the CARES Act was enacted. The CARES Act provided additional waivers, reimbursement, grants and other funds to assist health care providers during the COVID-19 pandemic, including $100.0 billion in appropriations for the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, to be used for preventing, preparing, and responding to the coronavirus, and for reimbursing eligible health care providers for lost revenues and health care related expenses that are attributable to COVID-19.

Through September 30, 2020, the Company’s consolidated subsidiaries received approximately $8.3 million of payments under the CARES Act (“Relief Funds”). Under the Company’s accounting policy, these payments have been recorded as Other income – Relief Funds. For the three and nine months ended September 30, 2020, the Company has recognized approximately $0.4 million and $8.3 million, respectively, as Other income – Relief Funds on the accompany consolidated statement of operations. These funds are not required to be repaid upon attestation and compliance with certain terms and conditions, which could change materially based on evolving grant compliance provisions and guidance provided by the U.S. Department of Health and Human Services. Currently, the Company can attest and comply with the terms and conditions. The Company will continue to monitor the evolving guidelines and may record adjustments as additional information is released.

Other Financial Measures

For the 2020 Third Quarter, the Company's Adjusted EBITDA was $19.9 million and was $17.0 million in the 2019 Third Quarter. For the 2020 Third Quarter, the Company's Adjusted EBITDA, excluding Relief Funds, was $19.5 million.

For the 2020 Nine Months, the Company's Adjusted EBITDA was $47.0 million compared to $ 57.5 million in 2019 Nine Months. For the 2020 Nine Months, the Company's Adjusted EBITDA, excluding Relief Funds, was $38.7 million.

See definition, explanation and calculation of Adjusted EBITDA in the schedule on pages 11 and 12.

Management’s Comments

Chris Reading, Chief Executive Officer, said, “When conditions are truly challenging, as they have been for much of this year, it makes all the difference to have a selfless, dedicated and driven team of partners and therapists, along with local and national support teams who are working hard every day to provide our patients with the excellent care they need conducted in a safe and healthy environment. Our team has delivered what I feel like is an exceptional result this quarter and an outstanding effort throughout this Covid-19 pandemic. As much as any time in my 17 years with our Company, I am truly proud to be able to work alongside such a tremendous group of people. While we have more work to do, I remain confident in our ability to navigate through the coming period and to execute on our plan to further grow, serve and expand our partner-centric Company.”

Larry McAfee, Chief Financial Officer, said, “Earnings per share from Operating Result of $.85 per share (excluding Relief Funds) was the most profitable quarter in the Company’s history. The previous high was $0.81 per share recorded in the second quarter of 2019.”

Third Quarter 2020 Conference Call

U.S. Physical Therapy's management will host a conference call at 10:30 a.m. Eastern Time, 9:30 a.m. Central Time, on November 5, 2020 to discuss results for the Company's third quarter and nine months ended September 30, 2020, 2020. Interested parties may participate in the call by dialing 1-888-335-5539 or 973-582-2857 and entering reservation number 5149266 approximately 10 minutes before the call is scheduled to begin. To listen to the live call via web-cast, go to the Company's website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived and can be accessed until February 5, 2021 at U.S. Physical Therapy’s website.

Forward-Looking Statements

This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 and the additional risk factor disclosed in our Quarterly Report on Form 10-Q for the period ended March 31, 2020 filed with the SEC on February 28, 2020 and May 21, 2020, respectively.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.

About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 550 outpatient physical therapy clinics in 39 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)

Three Months Ended

For the Nine Months Ended

September 30,
2020

September 30,
2019

September 30,
2020

September 30,
2019

Net patient revenues

$

96,398

$

104,392

$

268,803

$

324,405

Other revenues

12,531

12,859

36,700

35,450

Net revenues

108,929

117,251

305,503

359,855

Operating costs:

Salaries and related costs

57,519

66,748

169,952

203,684

Rent, supplies, contract labor and other

19,695

22,166

62,915

67,236

Provision for doubtful accounts

1,279

962

3,379

3,408

Closure costs - lease and other

79

3

2,066

12

Closure costs - derecognition of goodwill

-

-

1,859

-

Total operating costs

78,572

89,879

240,171

274,340

Gross profit

30,357

27,372

65,332

85,515

Corporate office costs

10,422

10,556

31,121

33,376

Operating income

19,935

16,816

34,211

52,139

Other income and expense

Relief Funds

390

-

8,349

-

Gain on sale of partnership interest and clinics

18

-

1,091

5,823

Interest and other income, net

50

7

97

27

Interest expense - debt and other

(351

)

(557

)

(1,431

)

(1,522

)

Total other income and expense

107

(550

)

8,106

4,328

Income before taxes

20,042

16,266

42,317

56,467

Provision for income taxes

4,279

3,197

8,453

11,223

Net income

15,763

13,069

33,864

45,244

Less: net income attributable to non-controlling interests:

Non-controlling interests - permanent equity

(1,828

)

(1,643

)

(3,889

)

(4,982

)

Redeemable non-controlling interests - temporary equity

(3,019

)

(2,379

)

(7,811

)

(8,152

)

(4,847

)

(4,022

)

(11,700

)

(13,134

)

Net income attributable to USPH shareholders

$

10,916

$

9,047

$

22,164

$

32,110

Basic and diluted earnings per share attributable to USPH shareholders

$

0.61

$

0.66

$

1.80

$

1.90

Shares used in computation - basic and diluted

12,847

12,774

12,829

12,750

Dividends declared per common share

$

-

$

0.30

$

0.32

$

0.84

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE DATA)

(unaudited)

September 30, 2020

December 31, 2019

ASSETS

(unaudited)

Current assets:

Cash and cash equivalents

$

30,129

$

23,548

Patient accounts receivable, less allowance for doubtful accounts of $2,154 and $2,698, respectively

39,439

46,228

Accounts receivable - other

9,878

9,823

Other current assets

3,198

5,787

Total current assets

82,644

85,386

Fixed assets:

Furniture and equipment

55,411

54,942

Leasehold improvements

34,111

33,247

Fixed assets, gross

89,522

88,189

Less accumulated depreciation and amortization

68,048

66,099

Fixed assets, net

21,474

22,090

Operating lease right-of-use assets

78,784

81,586

Goodwill

336,946

317,676

Other identifiable intangible assets, net

54,060

52,588

Other assets

1,530

1,519

Total assets

$

575,438

$

560,845

LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS

Current liabilities:

Accounts payable - trade

$

1,060

$

2,494

Accrued expenses

60,236

30,855

Current portion of operating lease liabilities

26,905

26,486

Current portion of notes payable

4,999

728

Total current liabilities

93,200

60,563

Notes payable, net of current portion

509

4,361

Revolving line of credit

7,000

46,000

Deferred taxes

8,570

10,071

Operating lease liabilities, net of current portion

60,137

60,258

Other long-term liabilities

349

141

Total liabilities

169,765

181,394

Redeemable non-controlling interests - temporary equity

139,801

137,750

U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity:

Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding

-

-

Common stock, $.01 par value, 20,000,000 shares authorized, 15,065,087 and 14,989,337 shares issued, respectively

151

150

Additional paid-in capital

93,195

87,383

Retained earnings

203,201

184,352

Treasury stock at cost, 2,214,737 shares

(31,628

)

(31,628

)

Total USPH shareholders’ equity

264,919

240,257

Non-controlling interests - permanent equity

953

1,444

Total USPH shareholders' equity and non-controlling interests

265,872

241,701

Total liabilities, redeemable non-controlling interests, USPH shareholders' equity and non-controlling interests

$

575,438

$

560,845

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)

Nine Months Ended

September 30,
2020

September 30,
2019

OPERATING ACTIVITIES

Net income including non-controlling interests

$

33,864

$

45,244

Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:

Depreciation and amortization

8,066

7,377

Provision for doubtful accounts

3,379

3,408

Equity-based awards compensation expense

5,325

5,262

Deferred income taxes

(834

)

3,680

Loss on sale of fixed assets

346

-

Gain on sale of partnership interest

(1,091

)

(5,823

)

Write-off of goodwill - closed clinics

1,859

-

Other

-

120

Changes in operating assets and liabilities:

Decrease (increase) in patient accounts receivable

4,117

(8,171

)

Decrease(increase) in accounts receivable - other

730

(1,006

)

Decrease (increase) in other assets

5,404

(2,744

)

Increase (decrease) in accounts payable and accrued expenses

13,495

(440

)

Decrease in other long-term liabilities

(58

)

(443

)

Net cash provided by operating activities

74,602

46,464

INVESTING ACTIVITIES

Purchase of fixed assets

(5,494

)

(7,428

)

Purchase of majority interest in businesses, net of cash acquired

(15,322

)

(30,365

)

Purchase of redeemable non-controlling interest, temporary equity

(3,087

)

(5,699

)

Purchase of non-controlling interest, permanent equity

(184

)

(138

)

Proceeds on sale of redeemable non-controlling interest, temporary equity

54

11,601

Proceeds on sales of partnership interest and clinics

674

-

Proceeds on sale of fixed assets

444

64

Net cash used in investing activities

(22,915

)

(31,965

)

FINANCING ACTIVITIES

Distributions to non-controlling interests, permanent and temporary equity

(14,223

)

(10,862

)

Cash dividends paid to shareholders

(4,110

)

(10,723

)

Proceeds from revolving line of credit

134,000

110,000

Payments on revolving line of credit

(173,000

)

(97,000

)

Principal payments on notes payable

(700

)

(1,409

)

Medicare Accelerated and Advance Payment Funds

12,924

-

Other

3

(17

)

Net cash used in financing activities

(45,106

)

(10,011

)

Net increase in cash and cash equivalents

6,581

4,488

Cash and cash equivalents - beginning of period

23,548

23,368

Cash and cash equivalents - end of period

$

30,129

$

27,856

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Cash paid during the period for:

Income taxes

$

4,421

$

9,458

Interest

$

1,202

$

1,412

Non-cash investing and financing transactions during the period:

Purchase of businesses - seller financing portion

$

796

$

4,300

Purchase of business - payable to common shareholders of acquired business

$

-

$

502

Purchase of redeemable non-controlling interest - notes payable

$

137

$

-

Payable due to purchase of redeemable non-controlling interest

$

699

$

283

Receivables related to sale of partnership interest

$

386

$

-

Notes receivables related to sale of partnership interest

$

670

$

2,780

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
OPERATING RESULTS AND ADJUSTED EBITDA
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)

The following tables provide detail of the diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results and Adjusted EBITDA. Management believes providing Operating Results and Adjusted EBITDA to investors is useful information for comparing the Company's period-to-period results.

Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders per the consolidated statement of net income plus charges incurred for closure costs less gain on sale of partnership interest and clinics, less allocated non-controlling interests, and excludes the ongoing CFO search, all net of tax. The earnings per share from Operating Results also excludes the impact of the revaluation of redeemable non-controlling interest. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is included in the earnings per basic and diluted share calculation, although it is not included in net income but charged directly to retained earnings.

Management uses Operating Results, which eliminates certain items described above that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.

Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and write-off of goodwill related to clinic closures. Management believes reporting Adjusted EBITDA is useful information for investors in comparing the Company’s period-to-period results as well as comparing with similar businesses which report adjusted EBITDA as defined by their company.

Operating Results and Adjusted EBITDA are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

OPERATING RESULTS AND ADJUSTED EBITDA

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2020

2019

2020

2019

Computation of earnings per share - USPH shareholders:

Net income attributable to USPH shareholders

$

10,916

$

9,047

$

22,164

$

32,110

Credit (charges) to retained earnings:

Revaluation of redeemable non-controlling interest

(4,298

)

(922

)

1,175

(10,752

)

Tax effect at statutory rate (federal and state) of 26.25%

1,228

242

(308

)

2,822

$

7,846

$

8,367

$

23,031

$

24,180

Earnings per share (basic and diluted)

$

0.61

$

0.66

$

1.80

$

1.90

Adjustments:

Charges incurred for CFO search

69

-

202

-

Closure costs

79

-

3,925

-

Gain on sale of partnership interest and clinics

(18

)

-

(1,091

)

(5,823

)

Relief Funds

(391

)

-

(8,349

)

-

Allocation to non-controlling interest

77

-

1,977

-

Revaluation of redeemable non-controlling interest

4,298

922

(1,175

)

10,752

Tax effect at statutory rate (federal and state) of 26.25%

(1,080

)

(242

)

1,184

(1,293

)

Operating Results (without Relief Funds)

$

10,880

$

9,047

$

19,704

$

27,816

Relief Funds

391

-

8,349

-

Allocation to non-controlling interest

(77

)

-

(1,753

)

-

Tax effect at statutory rate (federal and state) of 26.25%

(82

)

-

(1,731

)

-

Operating Results (including Relief Funds)

$

11,112

$

9,047

$

24,569

$

27,816

Basic and diluted Operating Results (without Relief Funds) per share

$

0.85

$

0.71

$

1.54

$

2.18

Basic and diluted Operating Results (including Relief Funds) per share

$

0.86

$

0.71

$

1.92

$

2.18

Shares used in computation - basic and diluted

12,847

12,774

12,829

12,750

Three Months Ended
September 30,

Nine Months Ended
September 30,

2020

2019

2020

2019

Net income attributable to USPH shareholders

$

10,916

$

9,047

$

22,164

$

32,110

Adjustments:

Depreciation and amortization

2,546

2,457

7,879

7,377

Closure costs - write-off of goodwill

-

-

1,859

-

Relief Funds

(391

)

-

(8,349

)

-

Interest income

(50

)

(7

)

(97

)

(27

)

Interest expense - debt and other

351

557

1,431

1,522

Provision for income taxes

4,279

3,197

8,453

11,223

Equity-based awards compensation expense

1,936

1,704

5,325

5,262

Adjusted EBITDA (without Relief Funds)

$

19,587

$

16,955

$

38,665

$

57,467

Relief Funds

391

-

8,349

-

Adjusted EBITDA

$

19,978

$

16,955

$

47,014

$

57,467

U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES

RECAP OF CLINIC COUNT

Date

Number of Clinics

March 31, 2019

590

June 30, 2019

564

September 30, 2019

574

December 31, 2019

583

March 31, 2020

567

June 30, 2020

554

September 30, 2020

550

U.S. Physical Therapy, Inc.

Larry McAfee, Chief Financial Officer

Chris Reading, Chief Executive Officer

(713) 297-7000

Three Part Advisors

Joe Noyons

(817) 778-8424

Source: U.S. Physical Therapy, Inc.

Categories

Business Wire Press Releases

Next Articles